Bioventix plc ("Bioventix" or the "Company") Holdings in CompanyBioventix plc (AIM: BVXP) was notified on 18 May 2015 that Adrian Williams nowhas a total beneficial holding of 253,372* ordinary shares of 5 pence each("Ordinary Shares") in the Company. This represents approximately 5.02% of theCompany's issued share capital.* Of the total holding, 237,534 are held in his own name, with the balance of 15,838 being held by DM plc, of which Mr Williams is the ultimate controlling party.For further information please contact:Bioventix plc Chief Executive Officer Tel: 01252 728 001Peter HarrisonfinnCap Ltd Corporate Finance Tel: 020 7220 0500Geoff Nash/Simon Hicks Corporate BrokingSteve NorcrossAbout Bioventix plc:Bioventix (www.bioventix.com) specialises in the development and commercialsupply of high-affinity monoclonal antibodies with a primary focus on theirapplication in clinical diagnostics, such as in automated immunoassays used inblood testing. The antibodies created at Bioventix are generated in sheep andare of particular benefit where the target is present at low concentration andwhere conventional monoclonal or polyclonal antibodies have failed to produce asuitable reagent. Bioventix currently offers a portfolio of antibodies tocustomers for both commercial use and R&D purposes, for the diagnosis ormonitoring of a broad range of conditions, including heart disease, cancer,fertility, thyroid function and drug abuse. Bioventix currently suppliesantibody products and services to the majority of multinational clinicaldiagnostics companies. Bioventix is based in Farnham, UK and its shares aretraded on AIM under the symbol BVXP.